

Ascorbic Acid Prevents the Genetic Damage induced by Cyclophosphamide in *In vitro* Human Lymphocytes

Keshava Rao K and Rudrama Devi .K*

Human Genetics and Toxicology, Department of Zoology, Osmania University, Hyderabad-Telangana, India

*Corresponding Author E-mail: rudramadevi_k@yahoo.com

Received: 9.11.2016 | Revised: 20.11.2016 | Accepted: 23.11.2016

ABSTRACT

Cyclophosphamide is one of most commonly used in malignant lymphomas. The antioxidants such as Vit C inhibits the toxicity of mutagens/carcinogens in animals and Humans. The protective effects of ascorbic acid (AA) on cyclophosphamide (CP) induced cytogenetic damage was evaluated using analysis of chromosomal aberrations in human lymphocytes in vitro. When cultures were treated with various doses of ascorbic acid there was no increase in the frequency of chromosomal aberrations in human lymphocyte cell cultures at all dose levels. But when AA was added to CP significant decrease in the percentage of chromosomal aberrations was observed in human lymphocytes vitC protects the CP in induced genetic damage in human lymphocyte cultures. Hence the results clearly indicate AA supplementation is safer in chemotherapy regimen for treatment of cancer. The VitC protects the cyclophosphamide induced genotoxicity in germ cells of mice. Hence VitC supplementation is safer in chemotherapeutic strategy.

Key words: Ascorbic acid, genotoxicity, cyclophosphamide, human lymphocytes.

INTRODUCTION

Cyclophosphamide, Cisplatin, Tamoxifen, Gemcitabine and Paclitxel etc., have shown clastogenic effects in various test systems. Potential genetic damage due to drugs and other chemicals is well recognized. Extensive studies have been carried out on mutagenicity of various drugs in microorganisms, insects, mammals and in exposed population^{2,33,46}. Cyclophosphamide (CPM) is a well-known bifunctional alkylating agent, widely used in cancer chemotherapy and expresses its genotoxicity when metabolically activated⁹. It

is extensively used for the treatment of various cancers as well as an immunosuppressant in organ transplantation, rheumatoid arthritis, systemic lupus erythromatosis, multiple sclerosis, and other benign diseases^{13,35}. According to the International Agency for Research on Cancer (IARC), CPM is widely used as reference mutagen and has been classified as carcinogenic for animals and humans⁴⁷.

There is considerable evidence that the effects of mutagenic and carcinogenic agents can be altered by many dietary constituents.

Cite this article: Rao, K.K. and Rudrama, D.K., Ascorbic Acid Prevents the Genetic Damage induced by Cyclophosphamide in *In vitro* Human Lymphocytes, *Int. J. Pure App. Biosci.* 4(6): 94-101 (2016). doi: <http://dx.doi.org/10.18782/2320-7051.2401>

Ascorbic acid (VC) is an essential dietary nutrient required as a co-factor for many enzymes and a very efficient antioxidant, scavenging reactive oxygen and nitrogen species and protecting cells against free radical mediated damage. Besides exerting antioxidant influence directly, VC can promote the removal of oxidative DNA damage from the DNA and/or nucleotide pool, through the up-regulation of repair enzymes⁷. The inhibitory effect of VC towards a number of mutagens/carcinogens was shown by many authors in humans and animals^{14,22,28}. The goal of the present study is to evaluate the in vivo protective effect of VC against the DNA damage induced by cyclophosphamide in mouse somatic cells. While most animals synthesize their own vitamin C, humans and few other animals, such as non human primates, guinea pigs and fruit bats do not. It is an active reducing agent involved in numerous biological effects and detoxification of many endogenous and exogenous compounds²¹. It is necessary in the body to form collagen in bones, cartilage, muscle and blood vessels and aids in the adsorption of iron²³. Some genotoxic effects of vitamin C in invitro test systems has been demonstrated but in invivo experiments there are no genotoxic effects^{5,16} in the present investigation analysis of chromosomal aberrations in human lymphocytes *in vitro*.

Dosage Schedule

In the present study two experiments were conducted. The animals were feed orally with cyclophosphamide and PFE extract and categorized in to following groups

Group I: controls with 0.5ml of physiological saline.

Group II: PFE extract 33 µg/ml

Group III: PFE extract 68 µg/ml

Group IV: PFE extract 114 µg/ml

In the second experiment for modulation studies all the three groups as follows:

Group I : controls with 0.5ml of physiological saline.

Group II: Cyclophosphamide 100 µg/ml

Group III: Cyclophosphamide 100 µg/ml + PFE extract 33 µg/ml

Group IV: Cyclophosphamide 100 µg/ml + PFE extract 68 µg/ml

Group V: Cyclophosphamide 100 µg/ml + PFE extract 114 µg/ml

Analysis of chromosomal aberrations in Human Lymphocytes

Intravenous blood of healthy human adults was collected aseptically using an anticoagulant heparin. Lymphocyte cultures were prepared and harvested according to the standard method prescribed by Moorhead *et al*³⁰ Lymphocyte cultures were initiated in RPMI 1640 medium containing 25% human AB serum, 0.5% PHA & 0.25% antibiotic Dicyclicin from Sigma Aldrich. The concentration of lead nitrate was 150 µg/ml and the ascorbic concentrations were calculated based on therapeutic dose. The doses were 3.33µg/ml, 8.33µg/ml and 16.33µg/ml. For priming experiments 150+3.33, 150+8.33 and 150+16.33 µg/ml were added to the cell cultures and at an interval of 0, 24 & 48 hrs. Simultaneously the control group cultures were also maintained. The cultures were grown at 37°C for 72 hrs. Later all cultures were terminated by adding colchicine (0.02%) to arrest the cell cycle at metaphase. After 2 h. of treatment the material was centrifuged at 1000 rpm for 10 min. The cells were treated with prewarmed hypotonic solution (KCl 0.08 M) for 20 min. After hypotonic treatment the cultures were centrifuged and the supernatant was removed, cells were fixed by adding chilled fixative (Methanol: Acetic acid 3:1). Later the slides were examined for various types of chromosomal aberrations such as chromatid gaps, breaks, acentric fragments. Isochromatid gaps, breaks and polyploids. Metaphases were scored per culture and the data was analyzed statistically using 2x2 contingency Chi-square test.

RESULTS

The results showed that the percentage of chromosomal aberration at 24 hrs treatments was increased from 2.00 in control to 2.25, 3.25 and 3.5 in cultures treated with 3.33, 8.33 and 16.66 g/ml ascorbic acid (Table 1). Similarly at 48 hrs the frequency of

chromosomal aberrations in cultures treated with 3.33, 8.33 and 16.66 g/ml ascorbic acid as 3.0, 3.25 and 3.75 as against 2.25 in control cultures. At 72 hrs treatment the frequencies of chromosomal aberrations were 1.5 in control cultures and it has increased to 4.0, 4.5 and 5.25 in 3.33, 8.33 and 16.66 g/ml ascorbic acid treated cultures. The overall incidences of frequencies were found to be statistically significant at all dose levels and all time intervals. ($P>0.05$, Table-1).

In the present study, the frequency of total chromosomal aberrations of Cyclophosphamide + Ascorbic Acid treated invitro human lymphocyte cultures were 0.80 in control 7.8 in 100 g/ml of cyclophosphamide treated cultures where as a decrease to 4.8,

4.20 and 3.0 was observed in Cyclophosphamide + Ascorbic Acid primed cultures i.e. 100+3.33 g/ml, 100+8.33 g/ml and 100+16.66 g/ml respectively at 24 hrs exposure (Table 2). Similarly at 48hrs 1.40 in control and 7.40 at 100 g/ml cp exposure and decreased after priming with ascorbic acid as follows 5.2, 4.4 and 3.4 with 100+3.33 g/ml, 100+8.33 g/ml and 100+16.33 g/ml conc. respectively. At 72 hrs controls were 1.8 and cp treated values are 7.6 and after priming with ascorbic acid with 100+3.33, 100+8.33 and 100+16.66 were 5.40, 5.0 and 3.6 respectively (Table-2). The data was statistically analysed and found to be significant (Table –2).

Table 1: Frequency of Chromosomal aberrations recorded in invitro human peripheral lymphocytes with various doses of Ascorbic Acid for 24, 48 and 72 hrs interval

Dose ($\mu\text{g/ml}$) and duration of treatment (hr)	24hrs		48 hr		72 hr	
	Normal metaphases scored (%)	Abnormal metaphases scored (%)	Normal metaphases scored (%)	Abnormal metaphases scored (%)	Normal metaphases scored (%)	Abnormal metaphases scored (%)
	Control	32 (98.00)	8 (2.0)	391 (97.75)	9 (2.25)	394 (98.5)
3.33 $\mu\text{g/ml}$	391 (97.75)	9 (2.25)*	388 (97.0)	12 (3.0)*	384 (96.0)	16 (4.0)*
8.33 $\mu\text{g/ml}$	387 (96.75)	13 (3.25)*	387 (96.75)	13 (3.25)*	382 (95.5)	18 (4.5)*
16.66 $\mu\text{g/ml}$	386 (96.5)	14 (3.5)*	385 (96.25)	15 (3.75)*	379 (94.75)	21 (5.25)*

* $P<0.05$

The values in parenthesis are percentages

Table 2: Frequency of Chromosomal aberrations recorded in invitro human peripheral lymphocytes analysed after for 24, 48 and 72 hrs in cyclophosphamide treated cultures primed with Ascorbic Acid

Dose Time	Non primed		Primed with ascorbic acid					
			3.33µg/ml		8.33µg/ml		16.66µg/ml	
	Normal metaphases scored (%)	Abnormal metaphases scored (%)	Normal metaphases scored (%)	Abnormal metaphases scored (%)	Normal metaphases scored (%)	Abnormal metaphases scored (%)	Normal metaphases scored (%)	Abnormal metaphases scored (%)
24 hours								
Control	492 (99.20)	8(0.80)						
Mitomycin	452 (90.40)	48 (9.60)*						
100 µg/ml	461 (92.20)	39 (7.80)*	476 (95.20)	24 (4.80)*	479 (95.80)	21 (4.20)*	485 (97.0)	15 (3.00)*
48 hours								
Control	493 (98.60)	7 (1.40)						
Mitomycin	450 (90.0)	50 (10.0)*						
100 µg/ml	463 (92.60)	37 (7.40)*	474 (94.80)	26 (5.20)*	478 (95.60)	22 (4.40)*	483 (96.60)	17 (3.40)*
72 hours								
Control	491 (98.2)	9(1.80)						
Mitomycin	451 (90.20)	49 (9.80)*						
100 µg/ml	462 (92.40)	38 (7.60)*	473 (94.60)	27 (5.40)*	485 (95.0)	25 (5.00)*	482 (96.40)	18 (3.60)*

*P<0.05

The values in parenthesis are percentages

DISCUSSION

Among the alkylating agents used for the treatment of wide range of cancers, CP is one of the widely used drugs. Acrolein and phosphoramidate are the active compounds of CP. These active compounds of the CP slow down the growth of cancerous cells by interfering with the actions of DNA within those cells. The mutagenicity of CP in particular is related to formation of the ultimate cytotoxic metabolite phosphoramidate mustard through the intermediate agents sine C. cause gene mutations, CA and rearrangements and aneuploidy in somatic cells as well as an increased frequency of secondary treatment-related tumors in human cancer survivors^{6,36}

Hence the development of effective modulatory hydroxycyclophosphamide and deschloroethylcyclophosphamide^{27,39} which is capable of inducing DNA crosslinks and strand lesions²⁰ It has been tested extensively for its genotoxic effects both *in vitro* and *in vivo* in different test systems giving consistently positive results¹⁸. Several lines of studies have demonstrated that the CP and many other chemotherapeutic agents cause gene mutations, CA and rearrangements and aneuploidy in somatic cells as well as an increased frequency of secondary treatment-related tumors in human cancer survivors^{6,36}. Hence the development of effective modulatory strategies for CP induced toxicity

will be of great importance for the chemotherapy for cancer. During the recent years much focus has been given for the search for natural compounds which modulates the drug/chemical induced toxicity^{28,44,45,48}. Several studies have clearly established the protective effects of various phytonutrients upon drug-induced toxicity^{8,25,26,37,40}.

The present work is an attempt to study the modulatory effect of Ascorbic acid in cyclophosphamide induced DNA damage in *in vitro*. Vit. C acts as either a free radical scavenger or pre-oxidant producing hydrogen peroxide and free radicals^{3,32,43}. As a physiological molecule ascorbic acid contributes to the natural antioxidant defense in cells Ascorbic Acid is considered to be most important antioxidant of plasma and at least in some cell types of the intracellular has ascorbate may be in mM range¹⁹ AA is not genotoxic in tests *in vivo* may be due to spatial separation of living organisms of the components of oxy radical generating system (namely AA, transition metal ions and oxygen, which has a much lower partial pressure in tissues than in the atmosphere) and also due to existence of an antioxidant system that inactivates oxygen radicals before their interaction with DNA¹⁵.

The results of the present study showed AA administration significantly decreases in chromosomal aberrations induced by lead nitrate in human lymphocytes *in vitro*. Numerous studies have showed antioxidant nature of vit C on DNA strand breakage in cell cultures^{11,17,31,34} Vit C supplementation however did not show a measurable protective effect against DNA damage⁴ and failed to protect the genotoxic damage caused by cisplatin based chemotherapy¹². The result are comparable with that konopacka *et al*²⁴ who noted the antioxidant vit C reduced the DNA damage before and after gamma ray irradiation of human lymphocytes in *in vitro*. Vit C also decreases chromosomal damage in Humans¹⁰ However Ahmed *et al*¹ reported that vit C reduce the frequency of chromosomal aberrations in peripheral blood lymphocyte cultures against hydrocortisone genotoxicity.

Similar results were obtained with AA added cultures when treated by chromium in *in vitro*. Similarly, the percentage of chromosomal aberrations were decreased by AA in cadmium chloride induced genetic damage in *in vitro* lymphocytes³⁸.

Interest in the chemo preventive functions of antioxidants has grown considerably in recent years. Evidence accumulated over the year's shows that people with high dietary intakes of fruits and vegetables are less likely to develop cancer than people who have low dietary intake of these foods. While many chemopreventives in fruits and vegetables may have anticancer properties, much interest has focused on vitamin C⁴¹. This study represents one of the premiere studies carried out to diminish the toxicity and the genotoxicity of the oxidative compound TMT by using the natural antioxidant compound VC. Vitamin C is a highly effective antioxidant. It acts as a reducing agent that can terminate free radical driven oxidation by being converted to a resonance-stabilized free radical. In this respect VC can protect indispensable molecules in the body, such as protein, lipids, carbohydrates and nucleic acids (DNA and RNA). VC also regenerates other antioxidants such as vitamin E⁴¹. Our results showed that concurrent administration of VC inhibited the DNA damage and chromosome aberrations induced by cyclophosphamide in all tested doses. The antioxidant properties of ascorbic acid could be an important factor in the protection against CP induced DNA damages and tissue toxicity and ascorbic acid has been reported as an anti sister chromatid exchanges induced by cyclophosphamide in mice. Earlier also the protective role of vitamin C against the mutagenic effects of various chemical agents i.e., cisplatin¹⁶ norethynodrel⁴⁵ and bleomycin⁴⁹ as well as cyclophosphamide⁴⁹ has been reported.

CONCLUSIONS

At this point of time more investigation is needed to delineate the down regulation pathways of modulatory actions of extract of

phyllanthus and which component of it is exerting effect on CP induced genotoxicity in human lymphocytes in *in vitro*. We here predict that this finding of ours give the directions for the future research possibilities for the design and development of plant extract related modulatory drugs in combination with the CP. Such drugs might minimize the side effects caused by the widely used chemotherapeutic agent CP.

Acknowledgement

The author (KRD) thankful to University authorities and Prof. B. Raghavender Rao, Former Head, Department of Zoology for providing necessary laboratory facilities .

REFERENCES

- Ahmad, S., Hoda, A. and Afzal, M., Additive action of vit. C and E against hydrocortisone induced genotoxicity in human lymphocyte chromosomes, *Int. J. Vitam Nuts Res Jul.*, **72(4)**: 9 (2004).
- Akram, H., Ghaderi Pakdel, F., Ahmadi, A. and Zare, S., Beneficial effects of American ginseng on epididymal sperm analyses in cyclophosphamide treated rats. *Cell J. Summer.*, **14(2)**: 116-21 (2012).
- Anderson, D., Antioxidant defences against reactive oxygen species causing genetic and other damage. *Mut. Res.*, **350**: 103-108 (1996).
- Anderson, D., Factors that contribute to biomarker responses in humans including a study in individuals taking Vit. C supplementation *Mut. Res.*, **480**: 337-347 (2001).
- Antunes, L.M.G. and Araujo, M.C.P., *darin J d Arc C B ianchi del.P. Mut, Res.*, **465**: 131-137 (2000).
- Ben Yehuda, D., Krichevsky, S. and Caspi, O., Microsatellite instability and p53 mutations in therapy related leukemia suggest mutator phenotype. *Blood*, **88**: 4296-4303 (1996).
- Cooke, M.S., Evans, M.D., Podmore, I.D., Podmore, K.E., Herbert, K.E., Mistry, N., Mistry, P., Hickenbotham, P.T., Hussieni, A., Griffiths, H.R. and Lunec, J., *FEBS Lett.*, **363**: 363-67 (1998).
- Darroudi, F., Targa, H. and Natarajan, A.T., Influence of dietary carrot on cytostatic drug activity of cyclophosphamide and its main directly acting metabolite: Induction of sister chromatid exchanges in normal human lymphocytes, Chinese hamster ovary cells and their DNA repair-deficient cell lines. *Mutat. Res.*, **198**: 327-335 (1988).
- Deshpande, S.S., Kewatkar, S.M. and Paithankar, V.V., Anticlastogenic activity of flavonoid rich extract of *Cassia auriculata* Linn. on experimental animal. *Indian J Pharmacol.*, **45(2)**: 184-6 (2013).
- Dusinska, M.I., Kazimirova, A., Barancokova, M., Beno, M., Smolkova, B., Horska, A., Raslova, K., Wsolova, L. and Collins, A.R., Nutritional supplementation with antioxidants decreases chromosomal damage in humans. *Mutagenesis*, **18**: 371-376 (2003).
- Duthie, S.J., Ma, A., Ross, M.A., and Collins, A.R., Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. *Cancer Res.* **56**: 1291-1295 (1996).
- Elsendoorn, T.J., Weijl, N.I., Mithoes, Zwindermann, A.H., Vandam, F., Dezwas, F.A., Tate, A.D. and Dsanto, S., Chemotherapy induced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo *Mut. Res.*, 498-158 (2001).
- Fleming, R.E., An overview of cyclophosphamide and ifosfamide pharmacology, *Pharmacotherapy*, **17**: 1465-1545 (1997).
- Fahmy, M.A., Hassan, N.H.A., Farghaly, A.A., Hassan, E.E.S., Holloway, D.F. and Peterson, F.J. in D, A. Roe and Campbell (eds) Marcel Dekker, New York. *Muta Res.*, **652**: 103-11 (2008).
- Gershoff, S.N., Vitamin C ascorbic acid new roles new requirements *Nutr. Rev.*,

- 51:** 313-326 (1993).
16. Giri. A., Khyndriam, D. and Prasad, S.B., *Mutat Res.*, (1998) **421:** 139-148.
 - Antunes, L.M.G., Araujo, M.C.P., Darin, J. d Arc C B ianchi del. P. *Mut. Res.*, **465:** 131-137 (2000).
 17. Green, M.H., Lowe, J.E., Waugh, A.P., Aldridge, K.E., Cole, J. and Arlett, C.F., Effect of diet and vitamin C on DNA strand breakage in freshly-isolated human white blood cells. *Mut. Res.*, **316:** 91-102 (1994).
 18. Hartmann, A., Herkommer, K., Gluck, M. and Speit, G., DNA-damaging effect of cyclophosphamide on human blood cells in vivo and *in vitro* studied with the single- cell gel test (comet essay). *Environ. Mol. Mutagen.*, **25:** 180-187 (1995).
 19. Halliwell, B., Vitamin C: antioxidant or pro-oxidant *in vivo*? *Free Radic. Res.*, **25:** 439-454 (1996).
 20. Hengstler, J.G., Hengst, A., Fuchs, J., Tanner, B., Pohl, J. and Oesch, F., Induction of DNA crosslinks and DNA strand lesions by cyclophosphamide after inactivation by cytochrome P – 450 2B1. *Mutat. Res.*, **373:** 215-223 (1997).
 21. Henson, D.E., Block, G. and Levine, M.J.. *Natl Cancer Inst.*, **83:** 547-550 (1991).
 22. Hassan, N.H.A., Fahmy, M.A., Farghaly, A.A. and Hassan, E.E.S., *Cytologia*, **71:** 213-22 (2006).
 23. Iqbal K Khan and Khattak A., *NMAK. Pakistan J Nutr.*, **3:** 5-13 (2004).
 24. Konopacka, M. and Rzeszowska-Wolny, J., Antioxidant vitamins C, E and beta-carotene reduce DNA damage before as well as after gamma-ray irradiation of human lymphocytes *in vitro*. *Mut. Res.*, **491:** 1-7 (2001).
 25. Kumar, K.B. and Kuttan, B., Chemoprotective activity of an extract of *Phyllanthus amarus* against cyclophosphamide induced toxicity in mice. *Phytomedicine*, **12:** 494-500 (2005).
 26. Kumaraguruparan, R., Chandramohan, K.V., Abraham, S.K. and Nagini, S., Attenuation of N-methyl -N'-nitro-N-nitrosoguanidine induced genotoxicity and oxidative stress by tomato and garlic combination. *Life Sci.*, **76:** 2247-2255 (2005).
 27. Le Blanc, G.A. and Waxman, D.J., Mechanisms of cyclophosphamide action on hepatic P-450 expression. *Cancer Res.*, **50:** 5720-5726 (1990).
 28. Madhavi, D., Devi, K.R., Rao, K.K. and Reddy, P.P., Modulating effect of phyllanthus fruit extract against lead genotoxicity in germ cells of mice. *J. Environ. Biol.*, **28:** 115-117 (2007).
 29. Mooney, L.A., Madsen, A.M., Tang, D., Orjuela, M.A., Tsai, W.Y., Garduno, E.R. and Perera, F.P., *Cancer Epidemiol Biomarkers Prev.*, **14:** 237-42 (2005).
 30. Moorhead, P.S., Nowell, P.C., Mellman, W.J., Batipps, D.N., and Hungerford, D.A., Chromosome preparations of leucocytes cultures from human peripheral blood. *Exp. Cell. Res.*, **20:** 613-616 (1960).
 31. Noroozi, M., Angerson, W.J. and Lean, M.E., Effects of flavonoids and vitamin C on oxidative DNA damage of human lymphocytes. *Am. J. Clin. Nutr.*, **67:** 1210-1218 (1998).
 32. Odin, A.P., Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. *Mut. Res.*, **386:** 39-67
 33. Padmalatha Rai, S. and Vijaylakshmi, K.K., Tamoxifen citrate induced sperm shape abnormalities in the *in vivo* mouse. *Mut. Res.*, **492:** 1-6 (2001).
 34. Paolini, M., Pozzetti, L., Pedulli, G.F., Marchesi, E. and Cantelli-Forti, G., The nature of prooxidant activity of vitamin C. *Life Sci.*, **64:** PL273-278 (1999).
 35. Perini, P., Calabrese, M., Rinaldi, L. and Gallo, P., The safety profile of cyclophosphamide in multiple sclerosis therapy. *Expert Opin Drug Saf.*, **6:** 183–190 (2007).
 36. Povirk, L. and Shuker, D., DNA damage and mutagenesis induced by nitrogen mustards. *Mutat. Res.*, **318:** 205-226 (1994).
 37. Premkumar, K., Kavitha, S., Santhiya,

- S.T. and Ramesh, A.R. Interactive effects of saffron with garlic and curcumin against cyclophosphamide induced genotoxicity in mice. *Asia. Pac. J. Clin. Nutr.*, **13**: 292-294 (2004).
38. Rajitha, N., Jayalaxmi, and Rudrama devi, K., Modulatory role of ascorbic acid against cadmium induced genotoxicity in invitro lymphocytes. *Environment & Toxicology*, (2008).
39. Ren, S., Yang, J.S., Kalthorn, T.F. and Slattery, J.T., Oxidation of cyclophosphamide to 4-hydroxy cyclophosphamide and deschloroethyl - cyclophosphamide in human liver microsomes. *Cancer Res.*, **57**: 4229-4235 (1997).
40. Rudrama devi, K. and Kusumlatha, C., Protective role of vitamin C against cytotoxicity induced by adriamycin in Mice. *International journal of pharma and Life sciences*, **2(11)**: 1195-1202 (2011).
41. Schneider, M., Diemer, K., Engelhart, K., Zankl, H., Trommer, W.E. and Biesalski, H.K., *Free Radic Res.*, **34**: 209-19 (2001).
42. Siddique, Y.H., Beg, T. and Afzal, *Advances. Env. Bio.*, **1(1)**: 27-32 (2007).
43. Shamberger, R.J., Genetic toxicology of ascorbic acid *Mut. Res.*, **133**: 135-159 (1994).
44. Shukla, Y. and Taneja, P., Antimutagenic effects of garlic extract on chromosomal aberrations. *Cancer Lett.*, **176**: 31-36 (2002).
45. Siddique, Y.H. and Afzal, M., Protective role of allicin and L-ascorbic acid against the genotoxic damage induced by chlormadinone acetate in cultured human lymphocytes. *Ind. J. Exp. Biol.*, **43**: 769-772 (2005b).
46. Smorenburg, C.H., Sparreboom, A., Bontenbal, M. and Verweij, J., Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. *Eur J Cancer*, **37**: 2310-23 (2001).
47. Uber, W.E., Self, S.E., Van Bakel, A.B., Pereira, N.L., Acute antibody-mediated rejection following heart transplantation. *Am J Transplant* **7**: 2064–2074 (2007).
48. Unnikrishnan, M.C., Soudamini, K.K., and Kuttan, R., Chemoprotection of garlic extract towards cyclophosphamide toxicity in mice. *Nutr. Cancer.*, **13**: 201-207 (1990).
49. Vijayalaxmi, K.K. and Venu, R., *Mut Res.*, **438**: 47-51 (1999).